Global Circulating Tumor Cells and Cancer Stem Cells Technologies Industry

NEW YORK, May 14, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Circulating Tumor Cells and Cancer Stem Cells Technologies Industry

http://www.reportlinker.com/p02116898/Global-Circulating-Tumor-Cells-and-Cancer-Stem-Cells-Technologies-Industry.html

This report analyzes the worldwide markets for Circulating Tumor Cells and Cancer Stem Cells Technologies in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 66 companies including many key and niche players such as -

Alchemia Limited
Amgen Inc.
Exelixis, Inc.
Formula Pharmaceuticals
GlaxoSmithKline Plc

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. CIRCULATING TUMOR CELLS (CTCS) - GLOBAL MARKET OVERVIEW II-1
CTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical
Biopsy II-1
Challenges in CTC Diagnostics II-2
Need for CTC Enrichment and Popular Methods II-3
CTC Enrichment Techniques II-3
CTC Identification - Various Approaches II-4
CTC IDENTIFICATION APPROACHES II-5
A List of mRNA Markers for RT-PCR-based Detection of CTCs by
Tumor Type II-6
CellSearch System™- The Only FDA Approved Automated
Enrichment/Isolation Technique II-7
Market Outlook II-7
Rising Incidence of Cancer - An Opportunity Indicator II-8
Table 1: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported in
Thousands for Asia-Oceania, Europe, North America, Latin
America & the Caribbean, and Africa (includes corresponding
Graph/Chart) II-8

Table 2: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer-Related Deaths in Thousands
for Asia-Oceania, Europe, North America, Latin America & the
Caribbean, and Africa (includes corresponding Graph/Chart) II-8

Table 3: New Cancer Cases in the World by Affected Site: 2012
(in Thousands) (includes corresponding Graph/Chart) II-9

Table 4: Global Incidence of Common Cancers in Men (2012):
Number of New Cases Reported in Thousands for Lung &
Bronchus, Prostate, Colorectal and Liver Cancers (includes
corresponding Graph/Chart) II-9

Table 5: Global Incidence of Common Cancers in Women (2012):
Number of New Cases Reported in Thousands for Breast,
Colorectal, Lung & Bronchus and Liver Cancers (includes
corresponding Graph/Chart) II-10

Table 6: Global Cancer Mortality in Men for Select Cancers
(2012): Number of Deaths in Thousands for Lung & Bronchus,
Liver, Colorectal and Prostate Cancers (includes
corresponding Graph/Chart) II-10

Table 7: Global Cancer Mortality in Women for Select Cancers
(2012): Number of Deaths in Thousands for Breast, Lung &
Bronchus, Colorectal and Liver (includes corresponding
Graph/Chart) II-11
Cancer Prone Sites based on Age II-11

2. MARKET TRENDS AND DRIVERS II-12
CTCs for Personalized Cancer Treatment II-12
Microfluidic Chip-based Technologies - A Promising Avenue for
Cancer Diagnosis II-12
CTC Microdevices Hog the Limelight II-12
Table 8: Select CTC Microdevices and Their Characteristics II-13
Limitations of CTC Technology for Point-of-Care Testing II-14
CTC Technologies Offer an Edge over Imaging Tests for Breast
Cancer Prognosis II-14
Limited Biomarkers Utilized In CTC Diagnostics - A Threat to
Market Growth? II-14

3. CANCER STEM CELLS - GLOBAL MARKET OVERVIEW II-16
CSC-Focused Innovations in Cancer Therapeutics II-16
Select Pathways or Molecular Targets for CSC Candidates II-17
Pipeline Analysis of Select Cancer Stem Cells Therapeutics (
2014) II-18
Select Targeted Toxins against CSC Markers: 2013 II-19
Various Methods Used for Isolation of Cancer Stem Cells II-19
Antibody-mediated Therapies II-20

4. CTC AND CSC RESEARCH FINDINGS & BREAKTHROUGHS II-21
Microfluidic Device with Micro-Hall Sensors Detect CTCs with
Higher Sensitivity and Specificity II-21
NBiomics Makes its Contribution to CTC Diagnosis II-21
Researchers at University of Michigan Develop Revolutionary
Capture CTCs Method II-21
Dean Flow Fractionation to Overcome Limitations Associated
with Conventional Biomarker Analysis II-22
Gold Nanoparticles Help in the Detection of CTCs II-22
Diabetes Drug Metformin May Prove Effective against Pancreatic
Cancer Stem Cells II-23
Novel Chemical Inhibitors that Target Cancer Stem Cells II-23

5. MEDICAL DIAGNOSTICS MARKET - A CONCEPTUAL OVERVIEW II-24
Clinical Diagnostics II-24
Table 9: Leading Players in the Global In Vitro Diagnostics
(IVD) Market (2013) - Market Share Breakdown by Value Sales
for Roche Diagnostics, Abbott Laboratories, Siemens, J&J,
Beckman Coulter, bioMerieux, and Others (includes
corresponding Graph/Chart) II-24

Table 10: Global In-Vitro Diagnostics (IVD) Market (2013):
Percentage Breakdown for Value Sales by Segment for Point of
Care, Immunity Tests, Clinical Chemistry, Nucleic Acid Tests,
Histology/Cytology, Microbiology, Haematology and Others
(includes corresponding Graph/Chart) II-25
Molecular Diagnostics - Growth Drivers II-25
Molecular Diagnostics for Lymphoid Malignancies II-25
Market Trends & Issues II-26
Global Molecular Diagnostics on a High Growth Curve II-26
Automation Driving Global Market II-26
Molecular Diagnostics: Marking Convergence of Numerous
Technologies II-26

Aging Population, Disease Incidence - Fundamental Drivers of
Growth II-27
Pharmaceutical Firms Carving their Niche in the Molecular
Diagnostics Market II-27
Limited Reimbursements by Third Party Payers - A Stumbling Block II-27
Molecular Diagnostics and Intellectual Property II-27
Business Opportunities in the Offing II-28
Medical Training and Practice Challenges II-28
Hurdles All the Way for Companies Eyeing Molecular Diagnostics II-28
Integration of Molecular Diagnostics into Therapeutics II-29
Molecular Diagnostics - Moving from Centralization to
Decentralization II-29

6. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS - ENRICHMENT,
IDENTIFICATION AND CHARACTERIZATION METHODS II-31
Introduction II-31
Enrichment II-31
Filtration (iSET) II-32
Density Gradient II-32
Immuno-magnetic Cell Enrichment II-32
Advantages of Different CTC Enrichment Procedures II-33
AdnaTest II-34
Identification II-34
1. PCR-Based Analysis II-34
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) II-34
RT-qPCR II-34
2. Cytometric Methods II-35

Fiber-Optic Array Scanning Technology (FAST) II-35
Laser Scanning Cytometry (LSC) II-35
Flow Cytometry II-35
CellSearch II-35
CTC-Chip II-36
Enzyme-linked Epithelial Immunospot Assay (ELISPOT) II-36
Fluorescence In Situ Hybridization (FISH) II-37
Vita-Assay® II-37
TelomeScan™ II-37
CytoTrack II-37
Some Other Methods for Detection of CTCs II-37
Characterization II-38
Chemo-Sensitivity Testing of CTCs II-39

7. CANCER STEM CELLS (CSCS) - BIOLOGY, ISOLATION, CSC SURFACE
MARKERS, AND SIGNALING PATHWAYS II-40
Introduction II-40
Differences between Normal Stem Cells and Cancer Stem Cells II-40
Milestones in Stem Cell and Cancer Stem Cell Research II-41
Origin II-42
Hierarchical versus Stochastic Models of Tumour Cell
Heterogeneity II-42
Isolation of Cancer Stem Cells II-43
Characteristics of Cancer Stem Cells II-43
Resistance to Chemotherapy II-43
Resistance to Radiation II-43
Invasion or Metastatic Activity II-43
CSC Markers II-43
EpCAM (Epithelial Cell Adhesion Molecule) II-43

CD133 (prominin 1) II-44
ALDH II-44
CD90 (THY1) II-44
CD44 (PGP1) II-44
CD24 (HSA) II-44
Surface Markers Used for the Identification of CSCs II-45
Cancer Stem Cell (CSC) Markers by Disease II-46
Metastatic Cancer Stem Cells II-46
Table 11: Cancer Stem Cells in Solid Tumors II-47
Pathways Involved in the Maintenance of CSCs II-47
p53 Pathway II-48
Activation of Receptor Tyrosine Kinase Pathway II-48
Notch Pathway II-48
Retinoblastoma Pathway II-48
Wnt and Sonic Hedgehog Pathways II-48
BMI-1 II-49
Research Indicates Diabetes Drug Metformin Effective against
Pancreatic Cancer Stem Cells II-49
Research Leads to Development of Novel Chemical Inhibitors
that Target Cancer Stem Cells II-49

8. PRODUCT LAUNCHES AND INTRODUCTIONS II-50
EU Authorisation for ANGLE's Parsortix Cancer Diagnostic Device II-50
ANGLE Launches Parsortix Device into the Research Market II-50
Promab Introduces New Range of Cancer Stem Cells Solutions II-50
Clearbridge BioMedics Unveils ClearCell® FX Cancer Cell
Enrichment System II-50
Fluxion Introduces New IsoFlux System CTC Technology II-51
Cynvenio Launches LiquidBiopsy Lab Service II-51
Biocept Launches OncoCEE-BR II-52
ApoCell to Launch ApoStream II-52

9. RECENT INDUSTRY ACTIVITY II-53
Stem Cell Therapeutics and University of York Ink Option
Agreement II-53
Veridex Undergoes Name Change to Janssen Diagnostics II-53
Janssen Diagnostics and Arno Therapeutics Ink Collaboration
Agreement II-53
Veridex Enters into Agreement with LabCorp II-53
Stemline Therapeutics Obtains Orphan Drug Designation for SL-401 II-54
ANGLE Announces Test Results of Parsortix Non-Invasive Cancer
Diagnostic Product II-54
University Health Network Signs Definitive License Agreement
with Stem Cell Therapeutics II-55
Verastem Inks Agreement with LabCorp® II-55
Verastem Receives Orphan Drug Designation for Defactinib from
US FDA II-55
Lonza Partners with Eclipse II-56
Verastem Signs Agreement with Pfizer to Acquire Exclusive In-
License Rights for VS-6063 II-56
ScreenCell Inks Global Distribution Agreement with Affymetrix II-56
Dainippon Sumitomo Pharma to Take Over Boston Biomedical II-57
Bionomics Takes Over Eclipse Therapeutics II-57
BioView Signs Commercial Collaboration Agreement with ScreenCell II-57

Coare Enters into a Services and Co-Marketing Alliance with
ChemDiv II-58
Eisai Signs Research Agreement with Verastem II-58
Fluxion Biosciences Inks Collaboration Agreement with Rubicon
Genomics II-59
Transgenomic Enters into Partnership with MD Anderson Cancer
Center II-59
Transgenomic Collaborates with NYU Langone Medical Center II-60
Veridex Receives China SFDA Approval for CellSearch® CTC Test
for Breast Cancer II-60
ScreenCell Signs Global Collaboration and Distribution
Agreement with Transgenomic II-60
OncoMed Pharmaceuticals Extends Collaboration with Bayer
Healthcare for New Cancer Drug II-61
Veridex Partners with Massachusetts General Hospital for CTC
Technology II-61

10. FOCUS ON SELECT MAJOR PLAYERS IN CTC DIAGNOSTICS II-62
Adnagen GmbH (Germany) II-62
ApoCell, Inc (US) II-62
Biocep LTD (Israel) II-62
Biocept, Inc. (US) II-62
Biofluidica Microtechnologies LLC (US) II-63
Celltrafix Inc. (US) II-63
Clearbridge Biomedics (Singapore) II-64
Creatv Microtech, Inc (US) II-64
Cynvenio Biosystems, Inc. (US) II-64
Ikonisys, Inc. (US) II-65
IVDiagnostics, Inc. (US) II-65
Janssen Diagnostics LLC (US) II-65
Epic Biosciences Inc (US) II-66
RARECELLS SAS (Italy) II-66
SCREENCELL (France) II-66
Stemcell Technologies, Inc. (Canada) II-67

11. SELECT MARKET PARTICIPANTS IN THE CANCER STEM CELLS (CSCS) SPACE II-68
Alchemia Limited (Australia) II-68
Amgen Inc. (US) II-68
Exelixis, Inc. (US) II-68
Formula Pharmaceuticals (US) II-68
GlaxoSmithKline Plc. (UK) II-69
Geron Corp. (US) II-69
Infinity Pharmaceuticals (US) II-69
Kalobios Pharmaceuticals Inc. (US) II-69
Novartis AG (Switzerland) II-69
OncoMed Pharmaceuticals, Inc. (US) II-70
Pfizer, Inc. (US) II-70
Roche Diagnostics (Switzerland) II-70
Verastem, Inc. (US) II-71

12. GLOBAL MARKET PERSPECTIVE II-72
Table 12: World Recent Past, Current & Future Analysis for
Circulating Tumor Cells (CTCs) Diagnostics by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 Through
2020 (includes corresponding Graph/Chart) II-72

Table 13: World Historic Review for Circulating Tumor Cells
(CTCs) Diagnostics by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) II-73

Table 14: World 15-Year Perspective for Circulating Tumor
Cells (CTCs) Diagnostics by Geographic Region - Percentage
Breakdown of Annual Revenues for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets for
Years 2006, 2014 & 2020 (includes corresponding Graph/Chart) II-74


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
US Diagnostics Market: An Overview III-1
CTC Diagnostics in the US - Set for a Strong Growth III-1
Cancer Incidence in the US III-1
Table 15: New Cancer Cases in the US by Gender and Affected
Site: 2012 III-2

Table 16: New Cancer Cases in Males in US by Leading Site:
2012 (includes corresponding Graph/Chart) III-3

Table 17: New Cancer Cases in Females in US by Leading
Site: 2012 (includes corresponding Graph/Chart) III-4
Research Breakthroughs in the US CTC Market III-4
Product Launches III-5
Strategic Corporate Development III-7
Select Key Players in CTC Market III-15
Select Key Players in CSC Market III-18
B.Market Analytics III-21
Table 18: The US Recent Past, Current & Future Analysis for
Circulating Tumor Cells (CTCs) Diagnostics Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 Through
2020 (includes corresponding Graph/Chart) III-21

Table 19: The US Historic Review for Circulating Tumor Cells
(CTCs) Diagnostics Analyzed with Annual Revenue Figures in
US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-21

2. CANADA III-22
A.Market Analysis III-22
Cancer Incidence in Canada III-22
Table 20: New Cancer Cases in Canada by Gender and Affected
Site: 2012 (includes corresponding Graph/Chart) III-22

Table 21: New Cancer Cases in Canada by Province: 2012
(includes corresponding Graph/Chart) III-23

Table 22: New Cancer Cases in Canada by Age Group: 2012
(includes corresponding Graph/Chart) III-24
Strategic Corporate Development III-24
Stemcell Technologies, Inc. - A Key Player III-25
B.Market Analytics III-25
Table 23: Canadian Recent Past, Current & Future Analysis
for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 Through
2020 (includes corresponding Graph/Chart) III-25

Table 24: Canadian Historic Review for Circulating Tumor
Cells (CTCs) Diagnostics Analyzed with Annual Revenue
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-26

3. JAPAN III-27
A.Market Analysis III-27
Strategic Corporate Development III-27
B.Market Analytics III-28
Table 25: Japanese Recent Past, Current & Future Analysis
for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 Through
2020 (includes corresponding Graph/Chart) III-28

Table 26: Japanese Historic Review for Circulating Tumor
Cells (CTCs) Diagnostics Analyzed with Annual Revenue
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-29

4. EUROPE III-30
A.Market Analysis III-30
Insight into Molecular Diagnostics Markets in Europe III-30
Table 27: European IVD Market for Select Countries (2010) -
Market Value in US$ Million for Spain, UK, Germany, Italy,
France, Poland, Netherlands, Belgium, Denmark, Portugal,
Austria, Sweden, Bulgaria and Lithuania (includes
corresponding Graph/Chart) III-31
Debt Crisis in Europe Affects Healthcare Industry III-31
Healthcare System . in a State of Transition? III-32
Cancer Trends III-32
Table 28: Cancer Incidence in Europe by Site: 2012 (in
Thousands) (includes corresponding Graph/Chart) III-33
ANGLE's Parsortix Cancer Diagnostic Device Obtains EU Approval III-33
B.Market Analytics III-34
Table 29: European Recent Past, Current & Future Analysis
for Circulating Tumor Cells (CTCs) Diagnostics by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest
of Europe Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2013 Through 2020 (includes
corresponding Graph/Chart) III-34

Table 30: European Historic Review for Circulating Tumor
Cells (CTCs) Diagnostics by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-35

Table 31: European 15-Year Perspective for Circulating Tumor
Cells (CTCs) Diagnostics by Geographic Region - Percentage
Breakdown of Annual Revenues for France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets for Years 2006,
2014 & 2020 (includes corresponding Graph/Chart) III-36

4a. FRANCE III-37
A.Market Analysis III-37
Screencell - A Key Player III-37
B.Market Analytics III-37
Table 32: French Recent Past, Current & Future Analysis for
Circulating Tumor Cells (CTCs) Diagnostics Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 Through
2020 (includes corresponding Graph/Chart) III-37

Table 33: French Historic Review for Circulating Tumor Cells
(CTCs) Diagnostics Analyzed with Annual Revenue Figures in
US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-38

4b. GERMANY III-39
A.Market Analysis III-39
An Overview of Molecular Diagnostics III-39
Key Player III-39
B.Market Analytics III-40
Table 34: German Recent Past, Current & Future Analysis for
Circulating Tumor Cells (CTCs) Diagnostics Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 Through
2020 (includes corresponding Graph/Chart) III-40

Table 35: German Historic Review for Circulating Tumor Cells
(CTCs) Diagnostics Analyzed with Annual Revenue Figures in
US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-41

4c. ITALY III-42
A.Market Analysis III-42
Rarecells Sas - A Key Player III-42
B.Market Analytics III-43
Table 36: Italian Recent Past, Current & Future Analysis for
Circulating Tumor Cells (CTCs) Diagnostics Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 Through
2020 (includes corresponding Graph/Chart) III-43

Table 37: Italian Historic Review for Circulating Tumor
Cells (CTCs) Diagnostics Analyzed with Annual Revenue
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-44

4d. THE UNITED KINGDOM III-45
A.Market Analysis III-45
Product Launch III-45
Strategic Corporate Developments III-45
GlaxoSmithKline Plc. - A Key Company Focusing on CSC
Therapeutics III-46
B.Market Analytics III-47
Table 38: The UK Recent Past, Current & Future Analysis for
Circulating Tumor Cells (CTCs) Diagnostics Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 Through
2020 (includes corresponding Graph/Chart) III-47

Table 39: The UK Historic Review for Circulating Tumor Cells
(CTCs) Diagnostics Analyzed with Annual Revenue Figures in
US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-48

4e. SPAIN III-49
Market Analysis III-49
Table 40: Spanish Recent Past, Current & Future Analysis for
Circulating Tumor Cells (CTCs) Diagnostics Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 Through
2020 (includes corresponding Graph/Chart) III-49

Table 41: Spanish Historic Review for Circulating Tumor
Cells (CTCs) Diagnostics Analyzed with Annual Revenue
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-50

4f. RUSSIA III-51
Market Analysis III-51
Table 42: Russian Recent Past, Current & Future Analysis for
Circulating Tumor Cells (CTCs) Diagnostics Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 Through
2020 (includes corresponding Graph/Chart) III-51

Table 43: Russian Historic Review for Circulating Tumor
Cells (CTCs) Diagnostics Analyzed with Annual Revenue
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-52

4g. REST OF EUROPE III-53
A.Market Analysis III-53
Select Players in CSC Markets III-53
B.Market Analytics III-54
Table 44: Rest of Europe Recent Past, Current & Future
Analysis for Circulating Tumor Cells (CTCs) Diagnostics
Analyzed with Annual Revenue Figures in US$ Million for
Years 2013 Through 2020 (includes corresponding Graph/Chart) III-54

Table 45: Rest of Europe Historic Review for Circulating
Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-55

5. ASIA-PACIFIC III-56
A.Market Analysis III-56
Cancer Trends in Asia-Pacific III-56
Table 46: Cancer Incidence in Asia-Oceania by Site: 2011
(in Thousands) (includes corresponding Graph/Chart) III-56
India III-57
China III-57
CellSearch Obtains Approval for Metastatic Breast Cancer
Detection in China III-57
Product Launch III-57
Strategic Corporate Developments III-58
Key Players III-58
B.Market Analytics III-59
Table 47: Asia-Pacific Recent Past, Current & Future
Analysis for Circulating Tumor Cells (CTCs) Diagnostics
Analyzed with Annual Revenue Figures in US$ Million for
Years 2013 Through 2020 (includes corresponding Graph/Chart) III-59

Table 48: Asia-Pacific Historic Review for Circulating Tumor
Cells (CTCs) Diagnostics Analyzed with Annual Revenue
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-60

6. REST OF WORLD III-61
A.Market Analysis III-61
Key Player III-61
B.Market Analytics III-61
Table 49: Rest of World Recent Past, Current & Future
Analysis for Circulating Tumor Cells (CTCs) Diagnostics
Analyzed with Annual Revenue Figures in US$ Million for
Years 2013 Through 2020 (includes corresponding Graph/Chart) III-61

Table 50: Rest of World Historic Review for Circulating
Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-62


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 66 (including Divisions/Subsidiaries - 67)

The United States (46)
Canada (3)
Japan (2)
Europe (9)
- France (3)
- Germany (2)
- The United Kingdom (1)
- Rest of Europe (3)
Asia-Pacific (Excluding Japan) (4)
Middle East (3)

To order this report: Global Circulating Tumor Cells and Cancer Stem Cells Technologies Industry
http://www.reportlinker.com/p02116898/Global-Circulating-Tumor-Cells-and-Cancer-Stem-Cells-Technologies-Industry.html 

_________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.